The purpose of this study is to evaluate the safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation. The hypothesis to be tested is that the cells are safe to infuse and that they have a positive clinical effect.
Patients with GVHD grade 2-4, will receive decidual stromal cells at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Intervention given within 7 days after corticosteroids.
Intervention given after 7 days after corticosteroids.
Karolinska Institutet
Stockholm, Sweden
Actuarial survival at one year after onset of graft versus host disease
Time frame: 12 months after inclusion
Response at 28 days after onset of graft versus host disease
Time frame: 28 days after inclusion
Side effects
Time frame: Up to 6 months after inclusion
Incidence of severe infections
Time frame: Up to 12 months after inclusion
Disease free survival
Time frame: 12 months after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.